UPR vs. UDG, ABC, HCM, CLIN, EMIS, ONT, GNS, INDV, VEC, and CTH
Should you be buying Uniphar stock or one of its competitors? The main competitors of Uniphar include UDG Healthcare (UDG), Abcam (ABC), HUTCHMED (HCM), Clinigen Group (CLIN), EMIS Group (EMIS), Oxford Nanopore Technologies (ONT), Genus (GNS), Indivior (INDV), Vectura Group (VEC), and CareTech (CTH). These companies are all part of the "medical" sector.
Uniphar vs.
UDG Healthcare (LON:UDG) and Uniphar (LON:UPR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
45.3% of Uniphar shares are owned by institutional investors. 10.1% of Uniphar shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
UDG Healthcare received 511 more outperform votes than Uniphar when rated by MarketBeat users. However, 100.00% of users gave Uniphar an outperform vote while only 74.68% of users gave UDG Healthcare an outperform vote.
Uniphar has a net margin of 1.68% compared to UDG Healthcare's net margin of 0.00%. Uniphar's return on equity of 13.18% beat UDG Healthcare's return on equity.
In the previous week, Uniphar had 2 more articles in the media than UDG Healthcare. MarketBeat recorded 2 mentions for Uniphar and 0 mentions for UDG Healthcare. Uniphar's average media sentiment score of 0.43 beat UDG Healthcare's score of 0.00 indicating that Uniphar is being referred to more favorably in the news media.
UDG Healthcare pays an annual dividend of GBX 0.17 per share. Uniphar pays an annual dividend of GBX 2 per share and has a dividend yield of 0.8%. UDG Healthcare pays out 0.7% of its earnings in the form of a dividend. Uniphar pays out 13.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Uniphar has higher revenue and earnings than UDG Healthcare. UDG Healthcare is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.
Uniphar has a consensus price target of GBX 310, suggesting a potential upside of 22.43%. Given Uniphar's stronger consensus rating and higher probable upside, analysts clearly believe Uniphar is more favorable than UDG Healthcare.
Summary
Uniphar beats UDG Healthcare on 13 of the 17 factors compared between the two stocks.
Get Uniphar News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:UPR) was last updated on 5/2/2025 by MarketBeat.com Staff
Buy UPR Stock Free UPR Stock Alerts